Biomarkers of Microvascular Glycocalyx Injury in Critical Illness

Abstract

The endothelial glycocalyx, a complex carbohydrate-rich layer lining the microvasculature, plays a pivotal role in vascular homeostasis. In critical illness, disruption of the glycocalyx has been implicated in the pathogenesis of organ dysfunction and adverse outcomes. Recent advances have identified several circulating biomarkers indicative of glycocalyx injury, offering both diagnostic and prognostic value. This review synthesizes current evidence on the molecular mechanisms, clinical significance, and practical applications of these biomarkers in the management of critically ill patients, and discusses recent advances and guideline recommendations for their use in clinical practice.

Introduction

Microvascular dysfunction is a hallmark of critical illnesses such as sepsis, acute respiratory distress syndrome (ARDS), trauma, and major surgery. The endothelial glycocalyx, a dynamic meshwork of proteoglycans, glycoproteins, and glycosaminoglycans, is fundamental to vascular barrier integrity, cell signaling, and inflammation modulation. Disruption of the glycocalyx has emerged as an early and central event in the pathophysiology of critical illness. The identification and quantification of circulating glycocalyx components as biomarkers offer unique insights into disease progression and therapeutic monitoring.

Epidemiology / Disease Burden

Glycocalyx injury is prevalent across a spectrum of critical illnesses, with studies demonstrating substantial shedding of glycocalyx constituents in up to 80% of patients with severe sepsis and septic shock. The burden is particularly high in intensive care units (ICUs), where incidence correlates with disease severity and mortality. The inability to noninvasively assess microvascular integrity in real time has historically limited epidemiological understanding, but the emergence of circulating biomarkers has clarified the scope and impact of glycocalyx disruption in the critically ill population.

Pathophysiology

The glycocalyx acts as a protective interface between blood and the endothelium, regulating vascular permeability, leukocyte adhesion, and coagulation. Inflammatory mediators, ischemia-reperfusion injury, oxidative stress, and enzymatic degradation (by heparanase and metalloproteinases) drive glycocalyx shedding. This results in loss of barrier function, increased vascular permeability, edema, and propagation of systemic inflammation. Shedding releases measurable fragments such as syndecan-1, heparan sulfate, and hyaluronic acid into the circulation, which serve as quantifiable indicators of microvascular injury.

Risk Factors

Risk factors for glycocalyx injury include the underlying critical illness (e.g., sepsis, trauma, ARDS), systemic inflammatory response, hyperglycemia, ischemia-reperfusion events, and aggressive fluid resuscitation. Patient factors such as advanced age, pre-existing cardiovascular or metabolic disease, and exposure to nephrotoxic agents may exacerbate injury. Recent evidence also implicates iatrogenic factors, including mechanical ventilation with high tidal volumes and certain vasoactive medications, in potentiating glycocalyx degradation.

Clinical Features

Although glycocalyx injury is not directly observable clinically, its consequences manifest as increased capillary leak, tissue edema, and end-organ dysfunction. Patients may present with hypotension, refractory shock, worsening oxygenation, and multi-organ failure. These features often parallel elevations of circulating glycocalyx biomarkers, providing indirect evidence of ongoing vascular injury and microcirculatory compromise.

Diagnosis

Diagnosis of glycocalyx injury relies on quantification of circulating components using immunoassays or mass spectrometry. Syndecan-1, heparan sulfate, hyaluronic acid, and soluble thrombomodulin are the most frequently measured biomarkers. Elevated plasma levels correlate with severity of illness and predict adverse outcomes. While direct visualization of the glycocalyx via intravital microscopy remains largely experimental, bedside sublingual videomicroscopy has shown promise in research settings. Integrating biomarker data with clinical and hemodynamic parameters enhances risk stratification and prognostication.

Treatment & Management

Management is primarily supportive and tailored to the underlying etiology. Early recognition and treatment of sepsis, judicious use of intravenous fluids, and avoidance of hyperglycemia are cornerstones of preserving microvascular integrity. Albumin and plasma may offer protective effects through restoration of colloid osmotic pressure and provision of glycocalyx constituents. Adjunctive therapies targeting inflammation and oxidative stress, such as corticosteroids and antioxidants, are under investigation. Close monitoring of biomarkers may guide fluid management and escalate interventions in high-risk patients.

Recent Advances / Emerging Therapies

Recent research has focused on the development of novel biomarkers and targeted therapies to protect or restore the glycocalyx. Recombinant antithrombin, sphingosine-1-phosphate analogues, and heparanase inhibitors have demonstrated potential in preclinical studies. Point-of-care assays for rapid syndecan-1 measurement are being evaluated for routine clinical use. Multi-omics approaches are elucidating new molecular signatures of glycocalyx injury, paving the way for precision medicine strategies in the ICU.

Guideline Recommendations

Current guidelines emphasize the importance of early sepsis recognition and hemodynamic optimization. While consensus recommendations for routine glycocalyx biomarker monitoring are not yet established, the Surviving Sepsis Campaign and European Society of Intensive Care Medicine highlight the need for individualized fluid therapy and minimization of iatrogenic injury. Ongoing clinical trials will inform future guidelines regarding integration of biomarker assessment into standard care pathways.

Conclusion

Biomarkers of microvascular glycocalyx injury provide valuable insights into the pathophysiology and prognosis of critical illness. Quantification of circulating glycocalyx components enables early detection of microvascular dysfunction, risk stratification, and potentially more targeted therapeutic interventions. As research evolves, integration of these biomarkers into routine clinical practice holds promise for improving outcomes in critically ill patients by guiding precision care and fostering the development of glycocalyx-protective therapies.